Views 200
Citations 0
Research Letter
January 23, 2019
Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers
Joanie Pinard, MD, FRCPC1; Alisa N. Femia, MD2; Michael Roman, BS2; et alAbeer Alsarheed, MD1; Cara Joyce, PhD3; Janice Lin, MD, MPH1,4; Ruth Ann Vleugels, MD, MPH1
JAMA Dermatol. Published online January 23, 2019. doi:10.1001/jamadermatol.2018.5215
Clinically amyopathic dermatomyositis (CADM), characterized by pathognomonic cutaneous findings without muscle weakness, is an important subset and accounts for 20% of patients with dermatomyositis (DM).1,2 In patients with CADM, limited literature exists regarding treatment specifically for cutaneous disease because many studies involve patients treated for pulmonary disease.3,4 Furthermore, no consensus exists on treatment for CADM. Given that there is often a discordance between the response of systemic and skin disease to therapy in DM and that cutaneous manifestations frequently represent a therapeutic challenge,3,4 studies focusing on treatment of skin disease in CADM remain an unmet need.
- Obtener vínculo
- X
- Correo electrónico
- Otras apps
Comentarios